Fennec Pharmaceuticals Inc. (FENC) stock
Close on Nov 11, 2026Market cap $373.12MP/E –Yield –
Fennec Pharmaceuticals Inc. grew revenue 71.1% to $66.37M over the twelve months to Sep 30, 2026. At the latest close the market valued the company at $373.12M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $373.12M
- P/E ratio
- –
- Price to sales
- 6.30
- Price to book
- 8.79
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $66.37M
- Net income
- $2.03M
- EPS, diluted
- $0.03
- Book value per share
- $1.29
- Diluted shares
- 38M
Trading
- Previous close
- $10.58
- Open
- $10.78
- Day's range
- $10.45 – $10.80
- Volume
- 268,815
- Average volume (20 days)
- 146,433
- Index membership
- Russell 2000 (since Jun 2023)
- Beta (5 years)
- 0.80
- 52-week range
- $5.65 – $13.25
- RSI (14 days)
- 52.0
- Volatility (1 year)
- 67.9%
- Relative volume
- 1.51×
- WACC
- 8.9%
Index membership is inferred from the holdings of funds that track each index (IWM), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2016, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | FENC | S&P 500 | Difference | FENC per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -0.7% | -2.4% | +1.7 pts | ||
| 3 months | -16.7% | -1.2% | −15.6 pts | ||
| Year to date | +38.2% | +12.3% | +25.9 pts | ||
| 1 year | +34.3% | +12.4% | +21.9 pts | ||
| 3 years | +40.4% | +78.8% | −38.4 pts | +12.0% | +21.4% |
| 5 years | +13.8% | +75.2% | −61.4 pts | +2.6% | +11.9% |
| 10 years | +491.1% | +311.1% | +180.0 pts | +19.4% | +15.2% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Fennec Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- News
- News
- News
- News
- Results
- News
About Fennec Pharmaceuticals
Biological Products, (No Diagnostic Substances)
Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on preventing cisplatin-induced hearing damage in cancer patients. Its primary commercial product is sodium thiosulfate injection, marketed as PEDMARK in the United States and PEDMARQSI in Europe, the United Kingdom, Australia, and New Zealand. The therapy reduces the risk of ototoxicity in pediatric patients aged one month and older who have localized, non-metastatic solid tumors and are receiving cisplatin chemotherapy. The company's end users are pediatric oncology patients, while its direct customers and distribution partners include hospitals, academic medical centers, community oncology clinics, specialty pharmacies, and international commercial partners.
Company profile, executives and historyFennec Pharmaceuticals stock: common questions
What is Fennec Pharmaceuticals's stock price?
FENC closed at $10.64 on Nov 11, 2026, up 0.57% on the day. Over the past 52 weeks it traded between $5.65 and $13.25.
What is Fennec Pharmaceuticals's market cap?
Fennec Pharmaceuticals was worth $373.12M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
How much revenue does Fennec Pharmaceuticals make?
Fennec Pharmaceuticals reported revenue of $66.37M for the twelve months to Sep 30, 2026, up 71.1% from a year earlier.
Does Fennec Pharmaceuticals pay a dividend?
No. Fennec Pharmaceuticals has not paid a cash dividend over the last twelve months.
How has FENC stock performed over the past year?
Including dividends, FENC returned +34.3% over the past year, against +12.4% for the S&P 500.
Who are Fennec Pharmaceuticals's competitors?
Companies most similar to Fennec Pharmaceuticals by business, industry and size include CHRS, BDTX, ADAPY, STRO, PTHS.
See a number that looks wrong?